Clinical Trial Update: Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study evaluating the combination BAY60-4552 with vardenafil for erectile dysfunction not adequately responsive to standard PDE5 inhibit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erectile Dysfunction

Drugs mentioned

• BAY60-4552 (BAY60-4552)
• Vardenafil (vardenafil)

Snippet

Sponsor: Bayer | Conditions: Erectile Dysfunction | Phase 2 | Status: COMPLETED